These results suggest the possibility of therapeutically targeting EPO signaling in NSCLC, and suggested blocking access to EPOR in tumor area may be helpful when rhEPO were used for chemotherapy-related anemia. This evidence concerns the gene EPOR and non-small cell lung carcinoma.